Skip to content

Author

Gurunathan RubhaShri

We have 1 of 1 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Multi-complex pharmacophore mapping for the repurposing of FDA drugs as HTLV-1 protease inhibitors: Toward novel anti-HTLV-1 therapeutics.

A multi-complex pharmacophore mapping approach was employed to explore the structural proteome of the HTLV-1 PR systematically, and the FDA-approved drug DB_FDA_1647 (Eliglustat) emerged as the most promising candidate, exhibiting favorable binding affinity, stable intermolecular interactions, and consistent structural...

Gurunathan RubhaShri, S. Singh · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.